nach oben

vorheriger Artikel Therapy management in bone sarcoma

Tipp

Screening for ovarian cancer: is there still hope?

Zeitschrift:: memo - Magazine of European Medical Oncology > Ausgabe 2/2020

Autoren:: PhD PD Dr. Stefanie Aust, Assoc. Prof. PD Dr. Veronika Seebacher-Shariat

» Zum Volltext PDF-Version jetzt herunterladen

Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Summary

Mainly diagnosed at advanced stage, ovarian cancer still remains the most lethal gynecological malignancy. Regarding screening and early detection, ovarian cancer poses particular challenges. To date, no screening test has been proven capable of leading to a mortality benefit. In this short review, we summarize and discuss the underlying literature on screening for ovarian cancer, focusing on average-risk, asymptomatic women as well as women at high risk. We also discuss the continuous advances and limits in liquid biopsies for early detection and screening of ovarian cancer.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Jetzt informieren

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. CrossRef

Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–53. CrossRef

Ray-Coquard I, Morice P, Lorusso D, Prat J, Oaknin A, Pautier P, et al. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv1–iv18. CrossRef

Carlson KJ, Skates SJ, Singer DE. Screening for ovarian cancer. Ann Intern Med. 1994;121(2):124–32. CrossRef

Zurawski VR Jr, Orjaseter H, Andersen A, Jellum E. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer. 1988;42:677–80. CrossRef

Jacobs I, Davies AP, Bridges J, Stabile I, Fay T, Lower A, et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ. 1993;306:1030–4. CrossRef

Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387(10022):945–56. CrossRef

Cramer DW, Bast RC Jr., Berg CD, Diamandis EP, Godwin AK, Hartge P, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res. 2011;4(3):365–74. CrossRef

Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA. 2011;305(22):2295–303. CrossRef

10.

Henderson JT, Webber EM, Sawaya GF. Screening for ovarian cancer: updated evidence report and systematic review for the US preventive services task force. JAMA. 2018;319(6):595–606. CrossRef

11.

Andersen MR, Drescher CW, Zheng Y, Bowen DJ, Wilson S, Young A, et al. Changes in cancer worry associated with participation in ovarian cancer screening. Psychooncology. 2007;16(9):814–20. CrossRef

12.

Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet. 1999;353(9160):1207–10. CrossRef

13.

Rosenthal AN, Fraser L, Manchanda R, Badman P, Philpott S, Mozersky J, et al. Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. J Clin Oncol. 2013;31(1):49–57. CrossRef

14.

Gronwald J, Lubinski J, Huzarski T, Cybulski C, Menkiszak J, Siolek M, et al. A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy. Gynecol Oncol. 2019;;155(2):270–74. https://doi.org/10.1016/j.ygyno.2019.08.034. CrossRefPubMed

15.

Committee on Practice Bulletins-Gynecology CoGSoGO. Practice bulletin no 182: hereditary breast and ovarian cancer syndrome. Obstet Gynecol. 2017;130(3):e110–e26. CrossRef

16.

Fiala C, Diamandis EP. New approaches for detecting cancer with circulating cell-free DNA. BMC Med. 2019;17(1):159. CrossRef

17.

Fiala C, Diamandis EP. Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection. BMC Med. 2018;16(1):166. CrossRef

18.

Singh A, Gupta S, Sachan M. Epigenetic biomarkers in the management of ovarian cancer: current prospectives. Front Cell Dev Biol. 2019;7:182. CrossRef

19.

Giannopoulou L, Zavridou M, Kasimir-Bauer S, Lianidou ES. Liquid biopsy in ovarian cancer: the potential of circulating miRNAs and exosomes. Transl Res. 2019;205:77–91. CrossRef

20.

Zhang W, Ou X, Wu X. Proteomics profiling of plasma exosomes in epithelial ovarian cancer: a potential role in the coagulation cascade, diagnosis and prognosis. Int J Oncol. 2019;54(5):1719–33. PubMedPubMedCentral

21.

Li J, Sherman-Baust CA, Tsai-Turton M, Bristow RE, Roden RB, Morin PJ. Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer. BMC Cancer. 2009;9:244. CrossRef

22.

Asante DB, Calapre L, Ziman M, Meniawy TM, Gray ES. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: ready for prime time? Cancer Lett. 2019;468:59–71. CrossRef

23.

Liggett TE, Melnikov A, Yi Q, Replogle C, Hu W, Rotmensch J, et al. Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors. Gynecol Oncol. 2011;120(1):113–20. CrossRef

24.

Ibanez de Caceres I, Battagli C, Esteller M, Herman JG, Dulaimi E, Edelson MI, et al. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res. 2004;64(18):6476–81. CrossRef

25.

Maritschnegg E, Heitz F, Pecha N, Bouda J, Trillsch F, Grimm C, et al. Uterine and tubal lavage for earlier cancer detection using an innovative catheter: a feasibility and safety study. Int J Gynecol Cancer. 2018;28(9):1692–8. CrossRef

Titel: Screening for ovarian cancer: is there still hope?
Autoren:: PhD PD Dr. Stefanie Aust
Assoc. Prof. PD Dr. Veronika Seebacher-Shariat
Publikationsdatum: 27.01.2020
DOI: https://doi.org/10.1007/s12254-019-00563-2
Verlag: Springer Vienna
Zeitschrift: memo - Magazine of European Medical Oncology An International Journal for Oncology and Haematology Professionals
Ausgabe 2/2020
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Publisher’s Note

Summary

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Weitere Artikel der Ausgabe 2/2020

The role of surgery in soft tissue sarcoma: Can we improve outcome and function towards sporting activities?

My personal highlights of ESMO 2019 regarding urogenital cancer

PARP inhibitors in the treatment of ovarian cancer

Diagnostic and therapeutic management of sarcoma patients

Hepatocellular carcinoma

Systemic therapy in advanced-stage hepatocellular carcinoma